Clinical Trials Directory

Trials / Unknown

UnknownNCT04915365

Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude

Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With Chronic Obstructive Pulmunary Disease (COPD) Traveling to High Altitude

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
University of Zurich · Academic / Other
Sex
All
Age
35 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this randomized, placebo-controlled double-blind trial is to evaluate the effect of acetazolamide on right heart function at rest in lowlanders with chronic obstructive pulmonary disease (COPD) traveling to high altitude (HA) and developing early signs of altitude-illness.

Detailed description

This randomized placebo-controlled, double-blind, parallel-design trial will evaluate effect of acetazolamide on right heart function in lowlanders with chronic obstructive pulmonary disease (COPD) travelling to high altitude and developping early symptoms and/or signs of impending altitude-illness. Qualifying participants will be randomized 1:1 to acetazolamide or placebo treatment during their further stay of 2 days at 3'100 m.

Conditions

Interventions

TypeNameDescription
DRUGAcetazolamideAcetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
DRUGPlaceboPlacebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.

Timeline

Start date
2021-05-01
Primary completion
2022-12-31
Completion
2023-12-31
First posted
2021-06-07
Last updated
2022-11-02

Locations

1 site across 1 country: Kyrgyzstan

Source: ClinicalTrials.gov record NCT04915365. Inclusion in this directory is not an endorsement.